Investing.com - CarMax, Chromadex and Intevac rallied into the close Friday despite a sea of red across Wall Street.
CarMax (NYSE:KMX), the largest seller of used vehicles in the U.S., reported fiscal third-quarter earnings that topped expectations, while revenue was in line, sending its shares more than 4% higher.
Wall Street was generally upbeat on CarMax's near-term outlook, though it warned that the fall in new car prices may weigh on the retailer's performance.
"Our proprietary tracker points to improving comp trends on easier comparisons in December-to-date, though we note a narrowing of the new/used price gap (as indicated by CPI data in November) is something worth monitoring," Wedbush Securities said in a note.
Pharma company Chromadex (NASDAQ:CDXC) continued to add to recent gains following its license and supply agreement with Nestle Health Science announced Thursday. Its shares rallied 19%.
Under the terms of the agreement, ChromaDex will provide Nestle exclusive right to its nicotinamide riboside ingredient Tru Niagen in exchange for an upfront payment of $4 million and royalty payments.
Intevac (NASDAQ:IVAC), a supplier of thin-film processing systems, surged 6% after it was awarded multiple contracts, boosting its Photonics backlog by more than $35 million.
The awards included a contract from the U.S. Military to develop digital night vision cameras over the next two years.